| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9a7099ace02f88c71bd8a6df6335936a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00119
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2015-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be45f567abc95c7268d2058539f5c0ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ce87cb794a38939217a563d3995ea5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3bb6f54a2fd81d825f5d594c5806e08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23f656e46431580b13366355510385ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7402eb4caa61425630aba173f741452b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21d8bb5a27b94713ac9a0ad1a0527ff6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9a858d43b5596da9d41a5de936ef619 |
| publicationDate |
2015-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015366957-A1 |
| titleOfInvention |
Melanoma-Associated MHC Class I Associated Oligopeptides and the Uses Thereof |
| abstract |
The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017147139-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109069604-A |
| priorityDate |
2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |